Feb 12 (Reuters) - Tivic Health Systems TIVC.O:
TIVIC HEALTH ACQUIRES EXCLUSIVE WORLDWIDE RIGHTS TO PHASE III TLR5 AGONIST FROM STATERA BIOPHARMA
TIVIC HEALTH SYSTEMS INC - TO PAY STATERA $1.2 MILLION IN EQUITY AND $300,000 CASH FOR ENTOLIMOD
Source text: ID:nBw6pThY2a
Further company coverage: TIVC.O